What is the Piramal Pharma PE ratio today?
Piramal Pharma's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit attributable to shareholders over the last four quarters (Q3 FY26 to Q2 FY27) was a loss of ₹209 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹30,657 crore at ₹230.78 a share.
What is the Piramal Pharma net worth?
Piramal Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹8,142 crore on 30 September 2026, up 0.8% from ₹8,074 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹30,657 crore at the 29 October 2026 close.
What is the Piramal Pharma book value per share?
Piramal Pharma's book value per share was ₹61.29 on 30 September 2026: shareholders' equity of ₹8,142 crore divided by the 132.84 crore shares in issue, up 0.6% from ₹60.91 a year earlier. The share price at the 29 October 2026 close was ₹230.78.
What is the Piramal Pharma PB ratio (price to book value)?
Piramal Pharma's price-to-book (PB) ratio is 3.77 at the 29 October 2026 close: a market capitalisation of ₹30,657 crore divided by shareholders' equity (book value) of ₹8,142 crore on 30 September 2026. That is a book value of ₹61.29 per share against a share price of ₹230.78.
What is the Piramal Pharma ROE and ROCE?
In FY26, Piramal Pharma's return on equity (ROE) was −4.0% and its return on capital employed (ROCE) was 0.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 1.1% and ROCE 5.5%.
What is the Piramal Pharma shareholding pattern?
On 30 September 2026, Piramal Pharma's shares were held by promoters 34.80%, foreign portfolio investors (FII/FPI) 13.65%, domestic institutions (DII) 14.44% (including mutual funds at 12.71%) and retail and other non-institutional investors 36.71%. Over the year, FII holding was down 16.62 percentage points from 30.27% and DII holding was down 0.45 percentage points from 14.89%.
What is the Piramal Pharma market cap?
Piramal Pharma's market capitalisation was ₹30,657 crore at the 29 October 2026 close: 132.84 crore shares at ₹230.78 each.
Is Piramal Pharma debt free?
No. Piramal Pharma had borrowings of ₹5,665 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.69. Its cash and current investments were ₹830 crore, so its net debt was ₹4,835 crore.
What is the Piramal Pharma EPS?
Piramal Pharma's basic earnings per share (EPS) were −₹2.46 in FY26. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to −₹1.58.
What is the Piramal Pharma debt to equity ratio?
Piramal Pharma's debt-to-equity ratio was 0.69 on 30 September 2026: borrowings of ₹5,665 crore against total equity of ₹8,165 crore. A year earlier, on 30 September 2025, it was 0.58.
What is the Piramal Pharma free cash flow?
In FY26, Piramal Pharma generated ₹1,653 crore of cash from operations and spent ₹890 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹763 crore. In FY25 it was ₹228 crore.
What is the Piramal Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Piramal Pharma's consolidated net loss was ₹326 crore, against a profit of ₹91.1 crore in FY25, on revenue from operations of ₹8,869 crore (down 3.1%).
What is the Piramal Pharma promoter holding?
Promoters held 34.80% of Piramal Pharma on 30 September 2026, unchanged from the previous quarter and down 0.06 percentage points from 34.86% a year earlier, according to the shareholding pattern filed with NSE.
What are the Piramal Pharma latest quarterly results?
Piramal Pharma's latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit attributable to shareholders ₹5.6 crore, against a loss of ₹99.2 crore in Q2 FY26; revenue from operations ₹2,617 crore, up 28.1% year on year.
When are the Piramal Pharma next results?
Piramal Pharma has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Piramal Pharma compare with its peers?
On FY26 consolidated figures, against Divi's Labs, Syngene International and Gland Pharma: Piramal Pharma's operating margin of 1.0% is the lowest of the four (Divi's Labs 28.2%, Syngene International 12.5%, Gland Pharma 18.8%; peer average 19.8%); its return on equity of −4.0% is the lowest of the four (Divi's Labs 16.2%, Syngene International 6.6%, Gland Pharma 10.5%; peer average 11.1%); its revenue growth over three years of 7.8% a year is the third highest of the four (Divi's Labs 10.8% a year, Syngene International 5.4% a year, Gland Pharma 21.1% a year; peer average 12.4% a year).
Piramal Pharma vs Divi's Labs: how do they compare?
In FY26, Piramal Pharma earned net profit attributable to shareholders of ₹326 crore on revenue of ₹8,869 crore, against ₹2,568 crore on ₹10,560 crore for Divi's Labs. Piramal Pharma's operating margin was 1.0% (Divi's Labs 28.2%) and its return on equity −4.0% (Divi's Labs 16.2%). At the 29 October 2026 close, Piramal Pharma's market capitalisation was ₹30,657 crore against ₹2,56,096 crore for Divi's Labs.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
